Cargando…

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

BACKGROUND: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24. METHODS: Patients (n = 380) with active axSpA were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poddubnyy, Denis, Pournara, Effie, Zielińska, Agnieszka, Baranauskaite, Asta, Jiménez, Alejandro Muñoz, Sadhu, Sanchayita, Schulz, Barbara, Rissler, Michael, Perella, Chiara, Marzo-Ortega, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544765/ https://www.ncbi.nlm.nih.gov/pubmed/34707696 http://dx.doi.org/10.1177/1759720X211051471

Ejemplares similares

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020)

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
por: Braun, Jürgen, et al.
Publicado: (2021)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

Old and new treatment targets in axial spondyloarthritis
por: Rios Rodriguez, Valeria, et al.
Publicado: (2015)

Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis
por: Poddubnyy, Denis
Publicado: (2020)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Treatment of Axial Spondyloarthritis: What Does the Future Hold?
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Defining the target: clinical aims in axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2018)

What is the optimal target for a T2T approach in axial spondyloarthritis?
por: Sieper, Joachim, et al.
Publicado: (2021)

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial
por: Behrens, Frank, et al.
Publicado: (2021)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2021)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
por: Sun, Yuankai, et al.
Publicado: (2022)

Choose wisely: imaging for diagnosis of axial spondyloarthritis
por: Diekhoff, Torsten, et al.
Publicado: (2022)

Correction to: Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
por: Harrison, S. R., et al.
Publicado: (2023)

Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
por: Aparicio, María, et al.
Publicado: (2021)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

COVID-19 in axial spondyloarthritis care provision: helping to straighten the long and winding road
por: Marzo-Ortega, Helena, et al.
Publicado: (2021)

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study
por: Ramonda, Roberta, et al.
Publicado: (2022)

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
por: Protopopov, Mikhail, et al.
Publicado: (2017)

Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results
por: Poddubnyy, Denis, et al.
Publicado: (2021)

Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
por: Kahn, Maria, et al.
Publicado: (2023)

Uveitis in spondyloarthritis
por: Rademacher, Judith, et al.
Publicado: (2020)

New bone formation at the sacroiliac joint in axial spondyloarthritis: characterization of backfill in MRI and CT
por: Diekhoff, Torsten, et al.
Publicado: (2023)

The need for comparative data in spondyloarthritis
por: Choy, Ernest, et al.
Publicado: (2019)

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2022)

The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data
por: Redeker, Imke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5apgaffv2um9rq6ktq300raorp